Metastatic Breast Cancer

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

CHICAGO — Sacituzumab govitecan continued to show significant improvement in OS among patients with heavily pretreated metastatic hormone receptor-positive breast cancer, according to final OS results of the phase 3 TROPiCS-02 study.

In this video, Paolo Tarantino, MD, discusses findings from the EMERALD phase 3 trial presented at San Antonio Breast Cancer Symposium.

In this video, Sara M. Tolaney, MD, MPH, discusses recent findings from DESTINY-Breast03 that assessed the use of fam-trastuzumab deruxtecan-nxki in previously treated patients with HER2-positive unresectable or metastatic breast cancer.

Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Longer duration of cyclin-dependent kinase 4/6 inhibitor therapy in the metastatic setting appeared associated with extended PFS among elacestrant-treated patients with advanced breast cancer, according to study results.

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, according to study findings.